Fully funded by 
Content independently selected
High-risk patients see an increase in RP rate.
Less than half of UK men with prostate cancer are offered any intervention for sexual dysfunction
Findings from BLEND study of 645,000 participants.
NCCN recommends SBRT as an alternative to conventionally fractionated regimens.
Phase 3 trial shows similar skeletal event-free survival, more bone fractures.
SEER-Medicare analysis shows higher risk than MVAC and CarboG.
NICE issues new guidance on electrically-stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer
No survival benefit observed for NACT with SCC histology.
More than 55% of men are not offered interventions for sexual dysfunction.
Centres located in competitive environments had short postoperative hospital stays and reduced readmission rates.
HIFU showed fewer pad-dependent patients, high-grade complications.
Phase 3 trial shows no benefit in patients experiencing PSA recurrence.
Digestive, urinary, and hematologic cancers are implicated.
NICE approves enzalutamide before chemotherapy is clinically indicated for metastatic, hormone-relapsed prostate cancer
Overall survival higher with partial nephrectomy.
Prostate cancer risk was similar in 18-year follow-up of PCPT.
Effect may be affected by type of first-line treatment.
